Clinical Trials Sponsored by Ayse Cal

Total 1868 results

CSL Behring

Completed

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Healthy

Germany
CSL Behring

Completed

Human Fibrinogen - Pharmacokinetics

Fibrinogen Deficiency

United States, Italy
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
CSL Behring

Completed

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Hereditary Angioedema

United States, Canada
CSL Behring

Completed

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure (BE1116_3003)

Reversal of Coagulopathy

United States, Belarus, Bulgaria, Lebanon, Romania, Russian Federation
CSL Behring

Completed

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

Bulgaria, United States, Poland, Spain, Hungary, United Kingdom, Russian Federation, Macedonia, The Former Yugoslav Republic of, Argentina, Australia, Canada, Czech Republic, Israel, Romania, Sweden
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery (REPLACE)

Surgical Blood Loss | Postoperative Blood Loss

United Kingdom, Canada, Japan, Italy, Poland, Germany, Czech Republic, Austria, Brazil, Denmark, Finland
CSL Behring

Completed

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Primary Immune Deficiency

United States
CSL Behring

Completed

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy

Poland, France, Germany, Belgium, Finland
CSL Behring

Completed

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

Common Variable Immunodeficiency | Agammaglobulinemia

Canada, Germany, Italy, Spain
CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
HAL Allergy

Completed

PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Belgium, Germany, Austria, Netherlands, Spain
HAL Allergy

Completed

SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Poland, Czech Republic, Germany
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
CSL Behring

Completed

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Common Variable Immunodeficiency | Agammaglobulinemia | IgG Deficiency

United States
CSL Behring

Completed

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States
HAL Allergy

Completed

Twin SUBLIVAC® Grasses Clinical Efficacy Study

Rhinitis, Allergic, Seasonal | Conjunctivitis, Allergic

Germany, Poland, Belgium, Netherlands
CSL Behring

Completed

Prothrombin Complex Concentrate for Anticoagulant Reversal

Acquired Coagulation Factor Deficiency

Austria, Germany, Hungary, Israel, Lithuania, Netherlands, Poland, Switzerland
CSL Limited

Completed

Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers

Healthy

Australia
CSL Limited

Completed

Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL

Acute Coronary Syndromes

Canada
CSL Behring

Recruiting

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Hereditary Angioedema (HAE)

United States, Israel
CSL Behring

Recruiting

Hizentra® in Inflammatory Neuropathies - pHeNIx Study (pHeNIx)

Chronic Inflammatory Demyelinating Polyneuropathy

France
CSL Behring

Active, not recruiting

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

Hemophilia B

United States, Belgium, Netherlands, Denmark, Germany, Ireland, Sweden, United Kingdom
CSL Behring

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (RECLAIIM)

Dermatomyositis

United States, Argentina, Belgium, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Spain, Switzerland, Ukraine
CSL Behring

Active, not recruiting

Respreeza® Self-administration and Learning Program (AmAREtTI Study) (AmAREtTI)

Alpha-1 Antitrypsin Deficiency

France
CSL Behring

Completed

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

Noncystic Fibrosis Bronchiectasis (NCFB)

United Kingdom, Germany
CSL Behring

Completed

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

Diabetic Kidney Disease (DKD)

United States, Australia, New Zealand, Puerto Rico, Canada, Israel
CSL Behring

Terminated

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Immune Complex-mediated Autoimmune Diseases

United Kingdom
CPL Associates

Completed

Characterization of Metabolic Biomarkers in Varying Subjects

Obesity | Type 2 Diabetes

United States
CSL Behring

Withdrawn

Fibrinogen Concentrate (Human) - Efficacy and Safety Study

Afibrinogenemia | Hypofibrinogenemia | Fibrinogen Deficiency
CSL Behring

Completed

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

Healthy Volunteers

United States
CSL Behring

Completed

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Hemophilia B

Germany, Denmark, Netherlands
CSL Behring

Completed

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 (COVID-19)

United States
CSL Behring

Completed

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Rheumatoid Arthritis

Italy, Japan, Taiwan, United States, Spain, Argentina, Belgium, Germany, Korea, Republic of, Czechia, Russian Federation, France, Mexico, Poland, South Africa, Hungary, Brazil, Canada, Netherlands
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
CSL Behring

Completed

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A | Severe Hemophilia A

United States, Australia, Austria, Canada, Czechia, France, Georgia, Germany, Hungary, Ireland, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, South Africa, Spain, Switzerland, Thailand, Ukraine, United...
CSL Behring

Terminated

Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults

Healthy

United Kingdom, Netherlands
CSL Behring

Completed

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Primary Immunodeficiency

United States, Canada
CSL Behring

Withdrawn

A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

PICC-associated Thrombosis
HAL Allergy

Completed

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Canada
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
HAL Allergy

Completed

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Rhinitis, Allergic | Rhinoconjunctivitis, Allergic

Canada
CSL Behring

Completed

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Germany, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
CSL Behring

Completed

Study of Voncento® in Subjects With Von Willebrand Disease

Von Willebrand Disease

Poland, Germany, Austria, Greece, United Kingdom
CSL Behring

Terminated

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

Hemophilia A

Russian Federation, Germany, Italy, Austria, Greece
CSL Behring

Completed

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Congenital Hemophilia A

United States, Austria, Germany, Malaysia, Netherlands, Philippines, Ukraine, Romania, Spain, Australia, France, Georgia, Italy, Lebanon, Poland, Portugal, Switzerland, Thailand, Turkey
HAL Allergy

Completed

SUBLIVAC FIX Birch Phase III Short-term Efficacy

Birch Pollen Induced Rhinitis/Rhinoconjunctivitis

Belgium, Germany, Czech Republic, Poland, Slovakia
CSL Behring

Completed

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Australia, Austria, Canada, Czech Republic, Germany, Hungary, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
CSL Limited

Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Australia

Clinical Trials Sponsored by Ayse Cal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations